louise, Author at ResoTher Pharma

RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK

ResoTher Pharma announces encouraging top-line results from its Phase 2a [...]

louise2026-09-15T08:52:34+00:00September 15, 2026|

“A completely new and very exciting funding opportunity,” combined with [...]

louise2026-01-13T18:52:10+00:00January 13, 2026|

ResoTher Pharma is pleased to announce that the first patient [...]

louise2024-09-17T17:08:03+00:00September 17, 2024|

Please read our biography published in Life Sciences Review 'Company [...]

louise2023-12-06T12:54:37+00:00December 6, 2023|

ResoTher Pharma, a biotech company focused on developing life-saving [...]

louise2023-11-07T11:01:44+00:00November 7, 2023|

Resother Pharma A/S (“ResoTher”) today announced the appointment of Anders [...]

louise2023-02-01T07:17:42+00:00February 1, 2023|

ResoTher Pharma is pleased to announce the appointment of Dr. [...]

louise2022-09-09T08:14:39+00:00September 1, 2022|

ResoTher Pharma today announced that the company has received approval [...]

louise2022-09-05T18:57:58+00:00December 15, 2021|

ResoTher Pharma is pleased to announce the appointment of Samra [...]

louise2022-09-05T18:57:49+00:00September 15, 2021|

ResoTher Pharma is pleased to announce the appointment of Teis [...]

louise2021-08-16T08:45:45+00:00August 16, 2021|